Ixazomib Citrate (MLN9708) Analogue

For research use only. Not for use in humans.

目录号:S2181 中文名称:柠檬酸伊沙佐米

Ixazomib Citrate (MLN9708) Analogue Chemical Structure

CAS No. 1201902-80-8

Ixazomib Citrate (MLN9708) Analogue 是 Ixazomib Citrate 的类似物,来自专利WO2016165677A1。Ixazomib Citrate (MLN9708) 在水溶液或血浆中可立即水解为具有生物活性的Ixazomib (MLN2238)。Ixazomib (MLN2238)抑制20S proteasome的胰凝乳蛋白酶等蛋白水解位点(β5),无细胞试验中IC50/Ki为3.4 nM/0.93 nM,对β1作用效果稍弱,对β2几乎没有抑制活性。Ixazomib (MLN2238) 可诱导自噬。Phase 3。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 2883.99 现货
RMB 1404.25 现货
RMB 7943.15 现货
RMB 20229.3 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Ixazomib Citrate (MLN9708) Analogue发表文献1篇:

客户使用该产品的3个实验数据:

  • LAT2 is degraded by proteasomes after treatment with alkylphospholipids. (A): 3-h treatment of NB4 cells before exposure to the proteasome inhibitor MG132 (10 M) prevented the reduction of LAT2 induced by 25 M ODPC. (B)(C): a similar effect was observed after exposure (30 min) of NB4 cells to the proteasome inhibitor MLN9708 (5 M) followed by treatment with 25 M ODPC (B) or 25 M perifosine (C).

    Mol Cell Proteomics, 2012, 11(12): 1898-912. Ixazomib Citrate (MLN9708) Analogue purchased from Selleck.

    Effect of proteasome inhibitors on [3H]-ryanodine binding. Panel A. Specific [3H]-ryanodine binding was measured in whole ventricle homogenates obtained in controls (C, white bars), after 30 min of ischemia (I, black bars) or after 30 min of ischemia followed by 60 minutes of reperfusion (IR, grey bars). MG132 was perfused at 0.5 μmol/L before ischemia (red bar, I) or from the very start of reperfusion (red bar, R). Values represent the mean ± S.E.M of different heartsas indicated in each bar *: p< 0.05 vs control or vs I + MG132. Panel B. Specific [3H]-ryanodine binding measured in hearts with the indicated concentration of ixazomib (ixa) perfused before ischemia. Values represent the mean ± S.E.M of values obtained in different hearts as indicated in each bar. *: p< 0.05 vs control

    PLoS One, 2016, 11(8):e0161068. Ixazomib Citrate (MLN9708) Analogue purchased from Selleck.

  • Structure and IC50 determination of ixazomib. Results represent means of three independent biological replicates, error bars indicate standard deviations. Smears were stained using DiffQuik staining set, parasitemia was counted at 1000 RBCs. Statistical analysis was performed in R using ANOVA. * = p < 0.05, *** = p < 0.001 (compared to the DMSO treated culture). Experimental conditions: starting parasitemia 2% (dotted line), medium with inhibitory compounds exchanged in 12 h intervals, total cultivation duration 48 h. DC: DMSO treated culture (0.008%). UC: untreated culture. IC50: half maximal inhibitory concentration. RBCs: red blood cells.

    Int J Parasitol Drugs Drug Resist, 2018, 8(3):394-402. Ixazomib Citrate (MLN9708) Analogue purchased from Selleck.

产品安全说明书

Proteasome抑制剂选择性比较

生物活性

产品描述 Ixazomib Citrate (MLN9708) Analogue 是 Ixazomib Citrate 的类似物,来自专利WO2016165677A1。Ixazomib Citrate (MLN9708) 在水溶液或血浆中可立即水解为具有生物活性的Ixazomib (MLN2238)。Ixazomib (MLN2238)抑制20S proteasome的胰凝乳蛋白酶等蛋白水解位点(β5),无细胞试验中IC50/Ki为3.4 nM/0.93 nM,对β1作用效果稍弱,对β2几乎没有抑制活性。Ixazomib (MLN2238) 可诱导自噬。Phase 3。
靶点
20S proteasome [1]
(Cell-free assay)
20S proteasome [1]
(Cell-free assay)
0.93 nM(Ki) 3.4 nM

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

溶解度 (25°C)

体外 DMSO 100 mg/mL (193.37 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
0.5% hydroxyethyl cellulose
30 mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 517.12
化学式

C20H23BCl2N2O9

CAS号 1201902-80-8
储存条件 粉状
溶于溶剂
别名 N/A

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03422874 Withdrawn Drug: MLN9708|Drug: Nelfinavir Neoplasms|Lymphoma Dartmouth-Hitchcock Medical Center August 2016 Phase 1
NCT02582359 Recruiting Drug: MLN9708|Drug: Cytarabine|Drug: Daunorubicin Acute Myeloid Leukemia Massachusetts General Hospital|Millennium Pharmaceuticals Inc. January 2016 Phase 1
NCT02250300 Completed Drug: MLN9708 Allogeneic Hematopoietic Stem Cell Transplantation Mehdi Hamadani|Medical College of Wisconsin November 19 2014 Phase 1|Phase 2
NCT01936532 Active not recruiting Drug: MLN9708|Drug: Lenalidomide|Drug: Dexamethasone Newly Diagnosed Multiple Myeloma Nantes University Hospital November 12 2014 Phase 2
NCT02168101 Completed Drug: MLN9708 Multiple Myeloma SCRI Development Innovations LLC|Millennium Pharmaceuticals Inc. September 2014 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项
免费分装抑制剂

Proteasome Signaling Pathway Map

Proteasome Inhibitors with Unique Features

相关Proteasome产品

Tags: 购买Ixazomib Citrate (MLN9708) Analogue | Ixazomib Citrate (MLN9708) Analogue供应商 | 采购Ixazomib Citrate (MLN9708) Analogue | Ixazomib Citrate (MLN9708) Analogue价格 | Ixazomib Citrate (MLN9708) Analogue生产 | 订购Ixazomib Citrate (MLN9708) Analogue | Ixazomib Citrate (MLN9708) Analogue代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID